Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter, randomized, double-blind, placebo-controlled phase III trial of a live attenuated influenza vaccine nasal spray in adults 18–59 years
CTR20253111Phase 3Active
- Sponsor
- Changchun Baimu Biotechnology
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of live attenuated influenza vaccine in influenza, sponsored by Changchun Baimu Biotechnology. Started Aug 2025; status: active.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20253111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253111.